Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890748488> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2890748488 endingPage "4012" @default.
- W2890748488 startingPage "4012" @default.
- W2890748488 abstract "4012 Background: We evaluated use of early PET response after induction chemotherapy (CT) to direct changing to alternative CT during preoperative chemoradiation (CRT) among patients (pts) with resectable esophageal and gastroesophageal junction (GEJ) adenocarcinomas who are PET nonresponders. We previously reported the primary endpoint of improving pathologic complete response (pCR) in PET nonresponders; pre-specified efficacy criteria were met for improvement in pCR rates with changing CT during CRT. We now report survival outcomes by PET response status. Methods: 257 pts enrolled, underwent baseline PET and were randomized to 1 of 2 induction CT arms: modified FOLFOX-6 (oxaliplatin, leucovorin, 5-FU) days 1, 15, 29 or carboplatin/paclitaxel (CP) days 1, 8, 22, 29. Repeat PET was performed days 36-42; change in maximum standardized uptake value (SUV) from baseline was assessed. PET nonresponders ( < 35% decrease in SUV: PET-NR) crossed over to alternative CT regimen during CRT (50.4 Gy/28 fractions). PET responders (≥35% decrease in SUV: PET-R) continued on same CT during CRT. Pts underwent surgery at 6 weeks post-CRT. Overall survival (OS) was measured from randomization to death from any cause; 2-year (yr) OS rates were estimated using the Kaplan-Meier method. Results: 240 eligible pts received protocol treatment and 222 had an evaluable repeat PET. With median follow-up of 35.9 months (mo) (95% CI: 33.1-41.2), median OS was 34.4 mo (95%CI: 28.4-49.7) and 2-yr OS was 61.8% (95%CI: 55.7-68.5%). Median OS for PET-R was 40.2 mo (95% CI:31.0, not estimable [NE]) and for PET-NR was 27.4 mo (95% CI: 20.3, NE). Median and 2-yr OS by induction CT and PET response appear below. Clinical trial information: NCT01333033. Conclusions: PET response after induction CT is prognostic for outcome in pts with esophageal and GEJ adenocarcinomas. Outcomes for PET-R pts receiving induction and concurrent FOLFOX are encouraging. Support: U10CA180821, U10CA180882 Response Group Events/N Median OS (mo) 95% CI (mo) 2-yr OS (%) 95% CI (%) CP N = 111 PET-R 31/63 31.0 (20.4, NE) 57.4 (46.2, 71.3) PET-NR 28/48 26.4 (16.0, NE) 52.4 (39.8, 69.0) FOLFOX N = 111 PET-R 29/72 48.7 (33.1, NE) 73.3 (63.4, 84.7) PET-NR 20/39 30.9 (25.4, NE) 64.0 (50.0. 82.0)" @default.
- W2890748488 created "2018-09-27" @default.
- W2890748488 creator A5006849637 @default.
- W2890748488 creator A5014994783 @default.
- W2890748488 creator A5021168714 @default.
- W2890748488 creator A5032746773 @default.
- W2890748488 creator A5035654935 @default.
- W2890748488 creator A5035865205 @default.
- W2890748488 creator A5037195553 @default.
- W2890748488 creator A5037875642 @default.
- W2890748488 creator A5054489256 @default.
- W2890748488 creator A5067136663 @default.
- W2890748488 creator A5071706562 @default.
- W2890748488 creator A5074891676 @default.
- W2890748488 creator A5076438320 @default.
- W2890748488 date "2018-05-20" @default.
- W2890748488 modified "2023-09-27" @default.
- W2890748488 title "Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer." @default.
- W2890748488 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.4012" @default.
- W2890748488 hasPublicationYear "2018" @default.
- W2890748488 type Work @default.
- W2890748488 sameAs 2890748488 @default.
- W2890748488 citedByCount "28" @default.
- W2890748488 countsByYear W28907484882018 @default.
- W2890748488 countsByYear W28907484882019 @default.
- W2890748488 countsByYear W28907484882020 @default.
- W2890748488 countsByYear W28907484882021 @default.
- W2890748488 countsByYear W28907484882022 @default.
- W2890748488 countsByYear W28907484882023 @default.
- W2890748488 crossrefType "journal-article" @default.
- W2890748488 hasAuthorship W2890748488A5006849637 @default.
- W2890748488 hasAuthorship W2890748488A5014994783 @default.
- W2890748488 hasAuthorship W2890748488A5021168714 @default.
- W2890748488 hasAuthorship W2890748488A5032746773 @default.
- W2890748488 hasAuthorship W2890748488A5035654935 @default.
- W2890748488 hasAuthorship W2890748488A5035865205 @default.
- W2890748488 hasAuthorship W2890748488A5037195553 @default.
- W2890748488 hasAuthorship W2890748488A5037875642 @default.
- W2890748488 hasAuthorship W2890748488A5054489256 @default.
- W2890748488 hasAuthorship W2890748488A5067136663 @default.
- W2890748488 hasAuthorship W2890748488A5071706562 @default.
- W2890748488 hasAuthorship W2890748488A5074891676 @default.
- W2890748488 hasAuthorship W2890748488A5076438320 @default.
- W2890748488 hasConcept C121608353 @default.
- W2890748488 hasConcept C126322002 @default.
- W2890748488 hasConcept C141071460 @default.
- W2890748488 hasConcept C168563851 @default.
- W2890748488 hasConcept C203092338 @default.
- W2890748488 hasConcept C204243189 @default.
- W2890748488 hasConcept C2776694085 @default.
- W2890748488 hasConcept C2778239845 @default.
- W2890748488 hasConcept C2779742542 @default.
- W2890748488 hasConcept C2780962732 @default.
- W2890748488 hasConcept C2781413609 @default.
- W2890748488 hasConcept C2781451048 @default.
- W2890748488 hasConcept C2989005 @default.
- W2890748488 hasConcept C526805850 @default.
- W2890748488 hasConcept C71924100 @default.
- W2890748488 hasConcept C90924648 @default.
- W2890748488 hasConceptScore W2890748488C121608353 @default.
- W2890748488 hasConceptScore W2890748488C126322002 @default.
- W2890748488 hasConceptScore W2890748488C141071460 @default.
- W2890748488 hasConceptScore W2890748488C168563851 @default.
- W2890748488 hasConceptScore W2890748488C203092338 @default.
- W2890748488 hasConceptScore W2890748488C204243189 @default.
- W2890748488 hasConceptScore W2890748488C2776694085 @default.
- W2890748488 hasConceptScore W2890748488C2778239845 @default.
- W2890748488 hasConceptScore W2890748488C2779742542 @default.
- W2890748488 hasConceptScore W2890748488C2780962732 @default.
- W2890748488 hasConceptScore W2890748488C2781413609 @default.
- W2890748488 hasConceptScore W2890748488C2781451048 @default.
- W2890748488 hasConceptScore W2890748488C2989005 @default.
- W2890748488 hasConceptScore W2890748488C526805850 @default.
- W2890748488 hasConceptScore W2890748488C71924100 @default.
- W2890748488 hasConceptScore W2890748488C90924648 @default.
- W2890748488 hasIssue "15_suppl" @default.
- W2890748488 hasLocation W28907484881 @default.
- W2890748488 hasOpenAccess W2890748488 @default.
- W2890748488 hasPrimaryLocation W28907484881 @default.
- W2890748488 hasRelatedWork W2022084568 @default.
- W2890748488 hasRelatedWork W2130806638 @default.
- W2890748488 hasRelatedWork W2373441140 @default.
- W2890748488 hasRelatedWork W2415897764 @default.
- W2890748488 hasRelatedWork W2465617904 @default.
- W2890748488 hasRelatedWork W2784153822 @default.
- W2890748488 hasRelatedWork W2884365279 @default.
- W2890748488 hasRelatedWork W2897495923 @default.
- W2890748488 hasRelatedWork W3110837088 @default.
- W2890748488 hasRelatedWork W4231341789 @default.
- W2890748488 hasVolume "36" @default.
- W2890748488 isParatext "false" @default.
- W2890748488 isRetracted "false" @default.
- W2890748488 magId "2890748488" @default.
- W2890748488 workType "article" @default.